Oral vancomycin: Treatment of primary sclerosing cholangitis in children with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 27, Issue 5, 1998, Pages 580-583

  Cox, Kenneth L ^a   Cox, Kathleen M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; VANCOMYCIN;

ADOLESCENT; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE; COLITIS; COLONOSCOPY; CROHN DISEASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-BACTERIAL AGENTS; BIOPSY; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; VANCOMYCIN;

CLOSTRIDIUM DIFFICILE;

EID: 0031782677     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199811000-00015     Document Type: Article

References (19)

1. Porayko MK, Weisner RH, LaRusso NF, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;98:1594-602.
2. Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
3. Balistreri WF, Bove KE. Sclerosing cholangitis. In: Suchy FJ, ed. Liver diseases in children. St. Louis: Mosby-Year Book, 1994: 622-37.
4. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-42.
5. Lindor KD, LaRusso NF, Wiesner RH. Prednisone and colchicine are not of benefit after two years in patients with primary sclerosing cholangitis (abstract). Hepatology 1989;10:638.
6. Weisner RH, Steiner B, LaRusso NF, Lindor KD, Baldus NP. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis (abstract). Hepatology 1991;14: 63A.
7. Knox TA, Kaplan MM. A double blind controlled trial of oral pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-99.
8. Beuers U, Spengler U, Kruis W. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis. A placebo-controlled trial. Hepatology 1992;16:707-14.
9. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30 month pilot study. Hepatology 1991;14:838-47 (Erratum Hepatology 1992;15:566.
10. Mitchell S, Bansi D, Hunt N, Christie J, Fleming K, Chapman R. High dose ursodeoxycholic acid (UCDA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial (abstract). Gastroenterology 1997; 112:A1335.
11. Lo SK, Herrmann R, Chapman RW. et al. Ursodeoxycholic acid in primary sclerosing cholangitis: A double-blind placebo controlled trial (abstract). Hepatology 1992;16:A92.
12. Van Thiel DH, Wright HI, Gavaler JS. Ursodeoxycholic acid (UCDA) therapy for primary sclerosing cholangitis (PSC): Preliminary report of a randomized controlled trial (abstract). Hepatology 1992;16:A62.
13. Di Febo G, Calabrese C, Matassoni F. New trends in non-absorbable antibiotics in gastrointestinal disease. Ital J Gastroenterol 1992;24:10-3.
14. Brooke BN, Dykes PW, Walker FC. A study of liver disorder in ulcerative colitis. Postgrad Med J 1961;37:245-8.
15. Ludwig J, Barham SS, LaRusso NF, Elveback LR, Weisner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981;1:632-40.
16. Carey JB Jr. Bile acids, cirrhosis, and human evolution. Gastroenterology 1964;46:490-3.
17. Siegel JH, Barnes S, Morris JS. Bile acids in liver disease associated with inflammatory bowel disease. Digestion 1977;15:469-81.
18. Hobson CH, Butt TJ, Ferry DM, Hunter J, Chadwick VS, Broom MF. Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. Gastroenterology 1988;94:1006-13.
19. Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992;90:1313-22.